Home » Chiron, MMRC Announce Initiation of Phase I Clinical Trial for CHIR-258
Chiron, MMRC Announce Initiation of Phase I Clinical Trial for CHIR-258
Chiron and the Multiple Myeloma Research Consortium (MMRC) announced the initiation of a Phase I clinical trial of CHIR-258 in multiple myeloma, a type of cancer.
CHIR-258, an orally available kinase inhibitor developed by Chiron, is the first drug candidate to undergo clinical study through the MMRC, a non-profit organization that integrates leading academic institutions with the goal of accelerating drug development in multiple myeloma.
The MMRC member institutions expected to enroll patients in the trial are Dana-Farber Cancer Institute, H. Lee Moffitt Cancer Center & Research Institute and the Mayo Clinic. Emory University also is expected to enroll patients in the trial.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct